KLOW
EVO Labs proprietary healing and recovery blend. KLOW combines BPC-157, TB-500, KPV, and GHK-CU for synergistic tissue repair, anti-inflammatory action, and systemic regeneration studied across multiple preclinical models.
Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How KLOW Works
KLOW combines four individually researched peptides into a single formulation targeting overlapping but distinct recovery pathways: BPC-157 drives angiogenesis and GI repair, TB-500 promotes actin-based cell migration, KPV provides anti-inflammatory immune modulation, and GHK-Cu stimulates collagen remodeling and tissue regeneration.
- VEGFR2 upregulation drives new capillary formation
- Nitric oxide modulation supports tissue perfusion
- Growth factor activation for fibroblast proliferation
- Thymosin Ξ²4 promotes actin polymerization
- Accelerates cell migration to injury sites
- Anti-fibrotic β reduces scar formation
- KPV: NF-ΞΊB suppression reduces inflammation
- GHK-Cu: stimulates collagen I/III synthesis
- GHK-Cu: activates TGF-Ξ² and MMP balance for matrix remodeling
The four peptides work in sequence: KPV reduces acute inflammation (NF-ΞΊB inhibition), BPC-157 initiates vascular repair (VEGFR2), TB-500 accelerates cell migration to injury sites (thymosin Ξ²4/actin), and GHK-Cu drives extracellular matrix remodeling (collagen/TGF-Ξ²). This creates a coordinated repair timeline from inflammation through regeneration.
EVO Labs Research formulation based on individually published peptide mechanisms.
Preclinical Findings
Research Models
Clinical Data
Multi-Peptide Synergy for Recovery Research
KLOW combines four peptides each with independent preclinical evidence. The blend is designed for research into synergistic recovery protocols across musculoskeletal, GI, dermal, and immune recovery pathways.
Individual component citations β see BPC-157, KPV, GHK-Cu research pages.
Preclinical data for individual components
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- Each component individually studied with favorable safety profiles
- BPC-157: No LD50 established in any animal model
- TB-500: Well-tolerated in wound healing and cardiac studies
- KPV: Endogenous Ξ±-MSH fragment β expected favorable safety
- GHK-Cu: Naturally occurring human plasma peptide
KLOW is a proprietary blend. Safety and efficacy data derives from individual component research. Synergistic effects have not been studied in clinical trials. For research use only.
About KLOW
EVO Labs proprietary healing and recovery blend. KLOW combines BPC-157, TB-500, KPV, and GHK-CU for synergistic tissue repair, anti-inflammatory action, and systemic regeneration studied across multiple preclinical models.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical (Prague, est. 2013). The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
 10MG.png)
